SCHEMBL319976

SCHEMBL319976

FC(F)(F)c1c[c]ncc1

nearest known ligand 0.39

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.39
NOS2 P35228 1/20 0.39
KIF11 P52732 2/20 0.38
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
BACE1 P56817 1/20 0.31
METAP2 P50579 1/20 0.31
ADRB1 P08588 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15093121 0.82
SCHEMBL604985 0.82
SCHEMBL16447219 0.82
SCHEMBL16446919 0.82
SCHEMBL601709 0.82
SCHEMBL4617682 0.80 NOS3 (0.31) NOS3NOS2
SCHEMBL17103477 0.79
SCHEMBL16538551 0.77 KIF11 (0.61) KIF11
SCHEMBL1499292 0.76 TSHR (0.40) TSHR
SCHEMBL29041259 0.76 NR1H2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US claimed
CN-112312913-B Compounds and uses thereof 詹森药业有限公司 2024-03-08 CN claimed
US-20240000767-A1 COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2024-01-04 US claimed
WO-2023227734-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-30 WO claimed
EP-4282862-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-29 EP claimed
US-20230357187-A1 Inhibitors of Dihydroceramide Desaturase For Treating Disease CENTAURUS THERAPEUTICS 2023-11-09 US claimed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US claimed
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US claimed
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US claimed
EP-4223753-A1 AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2023-08-09 EP claimed
EP-0586393-B1 SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES ZENECA LTD (GB) 1998-06-17 EP claimed
WO-1998001426-A1 COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-01-15 WO claimed
CN-1152909-A 2-(substituted phenyl)-2-alkoxyimino-n-alkylacetamide compound and bactericide containing the same SHIONOGI & CO (JP) 1997-06-25 CN claimed
EP-0777645-A1 OXIME ETHERS AND THEIR USE AS PESTICIDES Novartis AG (CH) 1997-06-11 EP claimed
EP-0760363-A1 2-(SUBSTITUTED PHENYL)-2-ALKOXYIMINO-N-ALKYLACETAMIDE COMPOUND AND BACTERICIDE CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 1997-03-05 EP claimed
WO-1996006072-A1 OXIME ETHERS AND THEIR USE AS PESTICIDES CIBA-GEIGY AG (CH) 1996-02-29 WO claimed
CN-1109686-A O-benzyl oxime ether derivatives and their use as pesticides CIBA GEIGY AG (CH) 1995-10-04 CN claimed
US-5439910-A For applying to plants, seeds or soils ZENECA LIMITED (GB) 1995-08-08 US claimed
EP-0651737-A1 O-BENZYL OXIME ETHER DERIVATIVES AND THEIR USE AS PESTICIDES Novartis AG (CH) 1995-05-10 EP claimed
WO-1994026700-A1 O-BENZYL OXIME ETHER DERIVATIVES AND THEIR USE AS PESTICIDES CIBA-GEIGY AG (CH) 1994-11-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 NOS3 3864/4885NOS2 3931/4885KIF11 3733/4885
US-20240000767-A1 COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA ADRA2C, ADRB2, CHRNA2 NOS3 2233/4885NOS2 3051/4885KIF11 4260/4885
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA NOS3 4167/4885NOS2 4360/4885KIF11 3944/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP NOS3 1203/4885NOS2 2248/4885KIF11 3684/4885
US-20230357187-A1 Inhibitors of Dihydroceramide Desaturase For Treating Disease CERS2, SMPD1, ASAH1 NOS3 2327/4885NOS2 2477/4885KIF11 4599/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP NOS3 1231/4885NOS2 2261/4885KIF11 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.